Evidence map›Paper›PMID 41444624›Full record

ReviewJournal of nanobiotechnology2025

Smart nanovehicles crossing the barricade: precision targeting of neuroinflammation for ischemic stroke diagnostics and therapeutics.

Shiyi Sun, Qiuhong Ouyang, Shaochan Zhang, Ruoyun Li, Ni Zhang, Xinglv Chen, Yaqi Zhang, Haochen Xie, Hui Lang, Chunqi Liu and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shiyi SunHainan Branch of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Haikou, China.
Qiuhong OuyangMental Health Center, Center for Preclinical Safety Evaluation of Drugs, Department of Neurology, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Shaochan ZhangHainan Branch of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Haikou, China.
Ruoyun LiHainan Branch of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Haikou, China.
Ni ZhangMental Health Center, Center for Preclinical Safety Evaluation of Drugs, Department of Neurology, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xinglv ChenMental Health Center, Center for Preclinical Safety Evaluation of Drugs, Department of Neurology, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yaqi ZhangHainan Branch of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Haikou, China.
Haochen XieHainan Branch of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Haikou, China.
Hui LangMental Health Center, Center for Preclinical Safety Evaluation of Drugs, Department of Neurology, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Chunqi LiuMental Health Center, Center for Preclinical Safety Evaluation of Drugs, Department of Neurology, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yi HouCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. houyi@iccas.ac.cn.
Meng QinMental Health Center, Center for Preclinical Safety Evaluation of Drugs, Department of Neurology, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. qinmeng212@scu.edu.cn.
Guibo SunHainan Branch of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Haikou, China. sunguibo@126.com.

Funding

1·3·5Project for Disciplines of Excellence, West China Hospital, Sichuan University ZYGD23011CAMS Innovation Fund for Medical Sciences 2021-I2M-1-031Key Research and Development Program of Hainan Province ZDYF2022SHFZ325National Natural Science Foundation of China 52473137Sichuan Provincial Natural Science Foundation 2024NSFSC1927
6 · The paper itself

Abstract

Neuroinflammation plays a critical role in the onset, progression, and clinical outcomes of ischemic stroke (IS). Real-time monitoring and targeted modulation of this neuroinflammatory cascade are essential for improving therapeutic efficacy. However, current diagnostic and therapeutic approaches are limited by poor blood-brain barrier (BBB) penetration, low specificity, and inadequate sensitivity in early stages. Engineered nanoparticles, with their tunable dimensions, customizable surface properties, and excellent biocompatibility, have emerged as promising vehicles for the precise diagnosis and targeted treatment of neuroinflammation in IS. In this review, recent advances in the application of various engineered nanoparticles for inflammation-focused diagnosis and therapy are summarized. Furthermore, current challenges and future directions for nanobiotechnology-based inflammatory interventions in IS are discussed.

Indexed as

Ischemic StrokeNanoparticlesNeuroinflammatory DiseasesAnimalsBlood-Brain BarrierDrug Delivery SystemsHumansInflammationDiagnosisIschemic strokeNanoparticlesNeuroinflammationTherapeutics

Identifiers

PMID41444624
PMCPMC12849130

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.